Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers

A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings.

Study: COVID-19 Infection Combined with Blood Clots Worsen Patient Outcomes

While respiratory issues continue to be the most common symptom of a COVID-19 infection, new research indicates the disease could also be associated with an increased tendency of the blood to clot, leading to a higher risk of death from COVID-19.